Prof. Zhang Boli, the Chief Inventor of Cardioshen® Dripping Pill Visits TCMzone Exhibit at ACAOM Continuing Education Conference in Houston TX

Cardioshen® Proven to Be Safe for Long Term Usage in a Large Clinical Trial in China

Zhang-boli_webHouston, TX. Feb 24. For those of us who practice Chinese medicine in the US, Prof. Zhang Boli (张伯礼) may not be a very recognizable name, but in China he is a very well-known person in the area of TCM. Prof. Zhang is an academician of The Chinese Academy of Engineering, among only a few selected Chinese medicine doctors who are members this prestigious organization. Prof. Zhang is the president of China Academy of Chinese Medical Sciences, the most influential research and clinical institution in China, employing over 3000 professional people working in 6 major hospitals and 13 research institutes in Beijing. He is also the president of Tianjin University of Traditional Chinese Medicine with currently over 9000 students on campus.

Over the past decades, Prof. Zhang has been a leading figure in developing Chinese medicine for the treatment of cardiovascular diseases, particularly the Dantonic® Pill, which is a principle drug for heart conditions in China and is now entering an FDA approved clinical phase III trial for the treatment of stable angina (for detail: http://clinicaltrial.gov/ct2/show/NCT01659580?term=tasly&rank=4). His newest research development is the invention of a next generation herbal medicine formula, Qishen Yiqi Dripping Pill which is used as prescription in China and marketed by TCMzone, LLC. in the US under the label of Cardioshen®.

Prof. Zhang Boli was invited to give a lecture at the Continuing Education Conference at American College of Acupuncture and Oriental Medicine (ACAOM), Houston TX, on Feb 23, 2013 (shown in picture above). During the conference, Prof. Zhang visited TCMzone’s exhibit table and met with Dr. Dan Wen, president of TCMzone, LLC. Dr. Wen highly praised the importance of the research program that Prof. Zhang led in basic science and clinical study of Qishen Yiqi Dripping Pill. Over the past years, there have been many research papers published. One of the most significant developments is a large post-marketing clinical trial on Qishen Yiqi Dripping Pill in China for its effect on improving heart health for people who have suffered a previous heart condition*. The 5-year study was performed in 84 hospitals by 450 physicians (Western and Chinese medicine) with 3508 patients. The patients were divided into two groups: Qishen Yiqi (1746 patients) vs. Aspirin (1760 patients) and all were on the therapy for 12 months. The results showed no difference between Qishen Yiqi Dripping Pill and Aspirin in the number of cardiovascular episodes and events during the study period. Qishen Yiqi is clinically proven to be a safe herbal formula for long term usage to improve heart health*.

“It’s such an honor to have Prof. Zhang lecture at ACAOM and show his support at TCMzone’s exhibit booth at the conference”, said Dr. Dan Wen, “the strong research data behind Cardioshen® is exactly what we need to educate American consumers on the safe and effective usage of Chinese herbal medicine”.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.